Whole genome expression analysis for biologic rational pathway modeling: Application in cancer prognosis and therapy prediction

Molecular Diagnosis and Therapy

Volumn 10, Issue 5, 2006, Pages 271-280

  Kemming, D ^a   Vogt, U ^b   Tidow, N ^c   Schlotter, C M ^d   Burger H ^e   Helms, M W ^f   Korsching, E ^e   Granetzny, A ^g   Boseila, A ^g   Hillejan, L ^g   Marra, A ^g   Ergonenc Y ^h   Adiguzel H ^h   Brandt, B ^a,i  

^a Institute for Tumor Biology   (Germany)

^b European Laboratory Association   (Germany)

^c Arrows Biomedical Deutschland GmbH   (Germany)

^d KLINIKUM IBBENBÜREN   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f STANFORD UNIVERSITY   (United States)

^g Klinik für Thoraxchirurgie   (Germany)

^h ST ANNA HOSPITAL   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; GEFITINIB; LAPATINIB; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; UROKINASE;

BIOSTATISTICS; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RISK; CANCER THERAPY; CHEMOLUMINESCENCE; CHROMOSOMAL INSTABILITY; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CLINICAL TRIAL; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; HIGH RISK POPULATION; HUMAN; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; OLIGONUCLEOTIDE PROBE; ONCOGENE MYC; PHENOTYPE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR GROWTH;

EID: 33749845827     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256202     Document Type: Review

References (50)

1. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70
2. Chou CC, Chen CH, Lee TT, et al. Optimization of probe length and the number of probes per gene for optimal microarray analysis of gene expression. Nucleic Acids Res 2004; 32: e99
3. Heller RA, Schena M, Chai A, et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci U S A 1997; 94: 2150-5
4. Kane MD, Jatkoe TA, Stumpf CR, et al. Assessment of the sensitivity and specificity of oligonucleotide (50mer) microarrays. Nucleic Acids Res 2000; 28 (22): 4552-7
5. Xu W, Bak S, Decker A, et al. Microarray-based analysis of gene expression in very large gene families: the cytochrome P450 gene superfamily of Arabidopsis thaliana. Gene 2001; 272: 61-74
6. Li J, Pankratz M, Johnson JA. Differential gene expression patterns revealed by oligonucleotide versus long cDNA arrays. Toxicol Sci 2002; 69: 383-90
7. Hughes TR, Mao M, Jones AR, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 2001; 19: 342-7
8. Hardiman G. Microarray platforms-comparisons and contrasts. Pharmacogenomics 2004; 5: 487-502
9. Kemming D, Tidow N, Wang A, et al. Chemiluminescent microarray analysis allows highly accurate expression profiling for established and downstream functional prognostic and predictive parameters in breast cancer [abstract no 436]. Presented at the 96th Annual Meeting of the Americal Association for Cancer Research; 2005 Apr 16-20; Anaheim. Proc Am Assoc Cancer Res 2005; 46: 101
10. Zaharkin SO, Kim K, Mehta T, et al. Sources of variation in affymetrix microarray experiments. BMC Bioinformatics 2005; 6: 214
11. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-93
12. Brown CS, Goodwin PC, Sorger PK. Image metrics in the statistical analysis of DNA microarray data. Proc Natl Acad Sci U S A 2001; 98: 8944-9
13. Chen Y, Chen Y, Dougherty ER, et al. Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Opt 1997; 2: 364-74
14. Huber W, von Heydebreck A, Sultmann H, et al. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 Suppl. 1: S96-104
15. Kroll TC, Wolfl S. Ranking: a closer look on globalisation methods for normalisation of gene expression arrays. Nucleic Acids Res 2002; 30: e50
16. Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002; 32 Suppl.: 496-501
17. Rajagopalan D. A comparison of statistical methods for analysis of high density oligonucleotide array data. Bioinformatics 2003; 19: 1469-76
18. Gautier L, Cope L, Bolstad BM, et al. Affy-analysis of affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-15
19. R Development Core Team. R: a language and environment for statistical computing. Viennna, Austria: R Foundation for Statistical Computing, 2006
20. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, et al., editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer, 2005: 397-420
21. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95: 14863-8
22. Tamayo P, Slonim D, Mesirov J, et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 1999; 96: 2907-12
23. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-7
24. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-21
25. Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002; 97 (454): 77-87
26. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003; 19: 2448-55
27. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002; 9: 505-11
28. Simon R, Radmacher MD, Dobbin K, et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14-8
29. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysts: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102 (42): 15545-50
30. Rennstam K, Ahlstedt-Soini M, Baldetorp B, et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis: a study of 305 tumors by comparative genomic hybridization. Cancer Res 2003; 63: 8861-8
31. Korsching E, Packeisen J, Helms MW, et al. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis relevated by comperative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer 2004; 90: 1422-8
32. Helms MW, Boecker W, Buerger H, et al. Impact of chromosome 7p-gains on gene expression in human breast cancer [abstract]. Breast Cancer Res Treat 2002; 76 Suppl. 1: S142
33. Helms MW, Packeisen J, August C, et al. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 2005; 206: 366-76
34. Brandt B, Roetger A, Dittmar T, et al. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogneic phenotype in human breast cancer cells. FASEB J 1999; 13: 1939-49
35. Dittmar T, Husemann A, Schewe Y, et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 2002; 16 (13): 1823-5
36. Thor AD, Eng C, DeVries S, et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol 2002; 33: 628-31
37. Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005; 128: 3975-84
38. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15: 28-32
39. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasis-associated receptor tyrosine kinases in non-small-cell lung cancer. Cancer Res 2005; 65: 1778-82
40. Feldner JC, Brandt BH. Cancer cell motility-on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002; 272: 93-108
41. Brandt B, Kemming D, Tidow N, et al. Assembling whole genome expression analysis data from snapshots of cancer cell conditions to decipher stages of differentiation. Cell Oncol 2005; 27: 95-6
42. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer: a study from the IMPACT trialists. J Clin Oncol 2005; 23: 2477-92
43. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5
44. Vogt U, Tidow N, Brandt B, et al. cDNA microarray profiling indicates selection of therapy resistant breast cancer cell clones in vivo. Am J Clin Oncol 2005; 23: 89S
45. Pusztai L, Gianni L. Technology insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nat Clin Pract Oncol 2004; 1: 44-50
46. Schlotter CM, Vogt U, Tidow N, et al. Semi-quantitative gene expression profiling for therapy prediction in a breast cancer neoadjuvant therapy study applying docetaxel/epirubicin/cyclophosphamide. Breast Cancer Res Treat 2005; 94: S226
47. Modlich O, Prisack HB, Munnes M, et al. Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 2005; 3: 32
48. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11: 2625-36
49. Selvanayagam ZE, Cheung TH, Wei N, et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 2004; 154: 63-6
50. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-9